Micofenolato Mofetile Tillomed Italia

Mycophenolate mofetil, the active ingredient in Micofenolato Mofetile Tillomed Italia, is an antimetabolite presented as an oral tablet for oral use. It is employed to prevent organ transplant rejection and to treat lupus nephritis by suppressing immune activity.

GNH USA supplies Micofenolato Mofetile Tillomed Italia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolate mofetil is an immunosuppressant that acts on T‑ and B‑lymphocyte proliferation in several transplant‑related and autoimmune conditions. - Organ transplant rejection: helps prevent acute rejection after kidney, heart or liver transplantation. - Lupus nephritis: reduces renal inflammation and proteinuria in patients with systemic lupus erythematosus. - Graft‑versus‑host disease prophylaxis: lowers the incidence of GVHD following hematopoietic stem cell transplantation.

Mycophenolate mofetil may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools that may require hydration. - Headache: transient cranial discomfort. - Tremor: fine shaking of hands or limbs. - Abdominal pain: crampy discomfort in the stomach area.

Serious or Rare Side Effects: - Severe infection: opportunistic infections due to immune suppression. - Leukopenia: marked reduction in white blood cells. - Anemia: decreased red blood cell count leading to fatigue. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Malignancy risk: increased incidence of certain cancers with long‑term use.

Before initiating therapy, clinicians should assess baseline laboratory values and patient risk factors. - Monitor blood counts: perform regular CBC to detect leukopenia or anemia. - Assess renal function: adjust therapy if creatinine clearance is reduced. - Contraindicated in pregnancy: avoid use due to teratogenic risk (Category X). - Avoid live vaccines: immunosuppression may permit uncontrolled infection. - Review concomitant nephrotoxic drugs: limit combined exposure to protect kidneys. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Mycophenolate mofetil can interact with several agents, altering efficacy or safety.

Major Interactions (Avoid): - Azathioprine: additive bone‑marrow suppression may cause severe cytopenias. - Ribavirin: combined immunosuppression increases infection risk. - Live vaccines: heightened risk of vaccine‑derived disease.

Moderate Interactions (Monitor Closely): - Cyclosporine: may raise mycophenolate plasma levels, requiring dose adjustment. - Tacrolimus: similar effect on mycophenolate exposure. - Antacids containing aluminum or magnesium: can reduce mycophenolate absorption; separate administration by at least 2 hours.